Literature DB >> 7989587

Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

M Schwabe1, A T Brini, M C Bosco, F Rubboli, M Egawa, J Zhao, G L Princler, H F Kung.   

Abstract

IL-6 is an autocrine growth factor for U266 myeloma cells and their growth is inhibited by IFN-alpha or IL-6 mAb. We asked, therefore, whether IFN-alpha-induced growth inhibition involved IL-6. IFN-alpha and mAb against IL-6, the IL-6R alpha-(gp80) or beta-chain (gp130) potently inhibited U266 cells. Remarkably, this effect occurred despite IFN-alpha-augmented secretion of endogenous IL-6. However, examining the IL-6R revealed that IFN-alpha drastically curtailed expression of the IL-6R alpha- and beta-chain. This effect occurred on two different levels (protein and mRNA) and by two different mechanisms (directly and indirectly through IL-6). First, IFN-alpha, but not IL-6, greatly decreased gp80 and, to a lesser extent, gp130 mRNA levels which resulted in a loss of IL-6 binding sites. Second, IFN-alpha-induced IL-6 predominantly down-regulated membrane-bound gp130. IFN-alpha-mediated decrease of gp80 levels was not detected on IL-6-independent myeloma (RPMI 8226) or myeloid cells (U937). We conclude that IFN-alpha inhibited IL-6-dependent myeloma cell growth by depriving U266 cells of an essential component of their autocrine growth loop, a functional IL-6R.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989587      PMCID: PMC330060          DOI: 10.1172/JCI117596

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

Authors:  B Klein; X G Zhang; M Jourdan; J Content; F Houssiau; L Aarden; M Piechaczyk; R Bataille
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

2.  Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia.

Authors:  A Biondi; V Rossi; R Bassan; T Barbui; S Bettoni; M Sironi; A Mantovani; A Rambaldi
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

3.  Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma.

Authors:  M Kawano; H Tanaka; H Ishikawa; M Nobuyoshi; K Iwato; H Asaoku; O Tanabe; A Kuramoto
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

4.  Interleukin 6 gene expression in normal and neoplastic B cells.

Authors:  G J Freeman; A S Freedman; S N Rabinowe; J M Segil; J Horowitz; K Rosen; J F Whitman; L M Nadler
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

5.  Response patterns of purified myeloma cells to hematopoietic growth factors.

Authors:  K C Anderson; R M Jones; C Morimoto; P Leavitt; B A Barut
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

Review 6.  Plasma cell myeloma--new biological insights and advances in therapy.

Authors:  B Barlogie; J Epstein; P Selvanayagam; R Alexanian
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

7.  A functional protein kinase C is required for induction of 2-5A synthetase by recombinant interferon-alpha A in Daudi cells.

Authors:  C R Faltynek; G L Princler; G L Gusella; L Varesio; D Radzioch
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

8.  Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.

Authors:  A Lasfar; J Wietzerbin; C Billard
Journal:  Eur J Immunol       Date:  1994-01       Impact factor: 5.532

9.  Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.

Authors:  L Bergui; M Schena; G Gaidano; M Riva; F Caligaris-Cappio
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

10.  Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression in human hepatocytes.

Authors:  J Bauer; T M Bauer; T Kalb; T Taga; G Lengyel; T Hirano; T Kishimoto; G Acs; L Mayer; W Gerok
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 2.  Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

Authors:  J Bladé; J Esteve
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

3.  Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

Authors:  D F Jelinek; K M Aagaard-Tillery; B K Arendt; T Arora; R C Tschumper; J J Westendorf
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

Review 4.  Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.

Authors:  A Faro
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Long-term survival in multiple myeloma: a single-center experience.

Authors:  Francesca Merchionne; Pasquale Procaccio; Franco Dammacco
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

Review 6.  Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.

Authors:  Hideaki Ishikawa; Naohiro Tsuyama; Michio M Kawano
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

7.  2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.

Authors:  B C Millar; J B Bell
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

8.  Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNalpha.

Authors:  Lun Song; Yan Li; Beifen Shen
Journal:  Cancer Cell Int       Date:  2002-07-08       Impact factor: 5.722

9.  Human P2X7 Receptor Causes Cycle Arrest in RPMI-8226 Myeloma Cells to Alter the Interaction with Osteoblasts and Osteoclasts.

Authors:  Ankita Agrawal; Lars S Kruse; Annette J Vangsted; Alison Gartland; Niklas R Jørgensen
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

10.  Comparative Cell Surface Proteomic Analysis of the Primary Human T Cell and Monocyte Responses to Type I Interferon.

Authors:  Lior Soday; Martin Potts; Leah M Hunter; Benjamin J Ravenhill; Jack W Houghton; James C Williamson; Robin Antrobus; Mark R Wills; Nicholas J Matheson; Michael P Weekes
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.